This clinical trial is focused on studying a condition known as Thyroid Eye Disease (TED). This is a condition where the muscles and tissues around the eyes become inflamed, which can lead to symptoms like bulging eyes, discomfort, and vision problems. The treatment being tested in this study is called VRDN-001, which is a type of medication known as an Insulin-like Growth Factor-1 Receptor (IGF-1R) inhibitor. This medication is designed to target specific proteins in the body that may be involved in the development of TED.

The purpose of this study is to confirm the safety and tolerability of VRDN-001 in people with TED. Participants in the study will receive five doses of VRDN-001 through an intravenous infusion, which means the medication is given directly into a vein. Each dose will be administered every three weeks. The study will monitor participants for any side effects and changes in their condition over a period of time.

Throughout the study, researchers will be looking at how participants respond to the treatment, including any changes in the symptoms of TED, such as the degree of eye bulging. The study aims to gather important information about the safety of VRDN-001 and how well it is tolerated by people with TED. This information will help in understanding the potential benefits and risks of using VRDN-001 as a treatment for this condition.